AU2005267185A1 - Bisarylurea derivatives useful for inhibiting CHK1 - Google Patents

Bisarylurea derivatives useful for inhibiting CHK1 Download PDF

Info

Publication number
AU2005267185A1
AU2005267185A1 AU2005267185A AU2005267185A AU2005267185A1 AU 2005267185 A1 AU2005267185 A1 AU 2005267185A1 AU 2005267185 A AU2005267185 A AU 2005267185A AU 2005267185 A AU2005267185 A AU 2005267185A AU 2005267185 A1 AU2005267185 A1 AU 2005267185A1
Authority
AU
Australia
Prior art keywords
pct
cancer
group
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005267185A
Other languages
English (en)
Inventor
Laurence Edward Burgess
Adam Wade Cook
Kimba L. Fischer
John Joseph Gaudino
Stephen T. Schlachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of AU2005267185A1 publication Critical patent/AU2005267185A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005267185A 2004-06-25 2005-06-24 Bisarylurea derivatives useful for inhibiting CHK1 Abandoned AU2005267185A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58308004P 2004-06-25 2004-06-25
US60/583,080 2004-06-25
PCT/US2005/022515 WO2006012308A1 (fr) 2004-06-25 2005-06-24 Dérivés de bisarylurée utiles pour inhiber chk1

Publications (1)

Publication Number Publication Date
AU2005267185A1 true AU2005267185A1 (en) 2006-02-02

Family

ID=35307890

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005267185A Abandoned AU2005267185A1 (en) 2004-06-25 2005-06-24 Bisarylurea derivatives useful for inhibiting CHK1

Country Status (9)

Country Link
EP (1) EP1765808A1 (fr)
JP (1) JP2008504283A (fr)
KR (1) KR20070028591A (fr)
CN (1) CN101006075A (fr)
AU (1) AU2005267185A1 (fr)
BR (1) BRPI0512593A (fr)
CA (1) CA2571424A1 (fr)
MX (1) MX2007000259A (fr)
WO (1) WO2006012308A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021002A2 (fr) * 2004-08-19 2006-02-23 Icos Corporation Composes utiles pour inhiber chk1
UA92164C2 (ru) * 2005-03-29 2010-10-11 Айкос Корпорейшен Соединения, пригодные для угнетения снк1
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
WO2023287839A2 (fr) * 2021-07-13 2023-01-19 Brown University Traitement du cancer du tractus urinaire guidé par le paysage mutationnel
WO2023056236A1 (fr) * 2021-09-28 2023-04-06 Pioneer Hi-Bred International, Inc. Conditions de germination et de croissance de semis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163723A (ja) * 1987-12-21 1989-06-28 Nippon Telegr & Teleph Corp <Ntt> 有機非線形光学材料
JPH09249628A (ja) * 1996-03-12 1997-09-22 Tanabe Seiyaku Co Ltd フェノール誘導体
CA2315715C (fr) * 1997-12-22 2010-06-22 Bayer Corporation Inhibition de la kinase p38 par des diphenyl-urees symetriques et dissymetriques
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2003022273A1 (fr) * 2001-09-13 2003-03-20 Boehringer Ingelheim Pharmaceuticals, Inc. Methodes de traitement de maladies mediees par la cytokine
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2003101444A1 (fr) * 2002-05-29 2003-12-11 Millennium Pharmaceuticals, Inc. Composes et derives de diaryluree utilises comme inhibiteurs de chk-1 dans le traitement du cancer

Also Published As

Publication number Publication date
JP2008504283A (ja) 2008-02-14
CA2571424A1 (fr) 2006-02-02
CN101006075A (zh) 2007-07-25
WO2006012308A1 (fr) 2006-02-02
EP1765808A1 (fr) 2007-03-28
BRPI0512593A (pt) 2008-03-25
KR20070028591A (ko) 2007-03-12
MX2007000259A (es) 2007-07-20

Similar Documents

Publication Publication Date Title
US7560462B2 (en) Compounds useful for inhibiting CHK1
EP1442019B1 (fr) Derives amides utilises en tant qu&#39;inhibiteurs de la glycogene synthase kinase 3-beta
ES2365504T3 (es) Inhibidores de chk1 de aril-urea y heteroaril-urea para su uso como radiosensibilizadores y quimiosensibilizadores.
US20080318974A1 (en) Compounds Useful for Inhibiting Chk1
EP1869020B1 (fr) Derives d&#39;uree d&#39;heteroaryle utilises pour inhiber chk1
JP2014141529A (ja) キナーゼのインヒビターとして有用なチアゾールおよびピラゾール
JP2008535830A5 (fr)
AU2005267185A1 (en) Bisarylurea derivatives useful for inhibiting CHK1
EA021067B1 (ru) Производные бензотиазолона

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application